Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents

Drugs and Aging

Volumn 13, Issue 4, 1998, Pages 269-280

  Flint, Alastair J ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN; PAROXETINE; PETHIDINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGED; AMNESIA; ANOREXIA; ANXIETY NEUROSIS; APATHY; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SEDATION; TACHYCARDIA; TREMOR; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

AGED; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; RISK ASSESSMENT;

EID: 0031784740     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813040-00003     Document Type: Review

References (97)

1. Blazer DG. Epidemiology of late-life depression. In: Schneider LS, Reynolds CF, Lebowitz BD, et al., editors. Diagnosis and treatment of depression in late life. Washington, DC: American Psychiatric Press; 1994: 9-19
2. NIH Consensus Development Panel. Diagnosis and treatment of depression in late life. JAMA 1992; 268: 1018-24
3. Crome P. Drug compliance in the elderly. In: Wheatley D, editor. Psychopharmacology of old age. Oxford: Oxford University Press; 1982: 55-64
4. Reynolds CF, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: a post hoc comparison of elderly ('young old') and midlife patients. Am J Psychiatry 1996; 153: 1288-92
5. Gerson SC, Plotkin DA, Jarvik LF. Antidepressant drug studies. 1964-1986: empirical evidence for aging patients. J Clin Psychopharmacol 1988; 8: 311-22
6. Volz HP, Möller HJ. Antidepressant drug therapy in the elderly: a critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry 1994; 27: 93-100
7. Anstey K, Brodaty H. Antidepressants and the elderly: double-blind trials 1987-1992. Int J Geriatr Psychiatry 1995; 10: 265-79
8. Menting JEA, Honig A, Verhey FRJ, et al. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. Int Clin Psychopharmacol 1996; 11: 165-75
9. Schneider LS. Pharmacologic considerations in the treatment of late-life depression. Am J Geriatr Psychiatry 1996; 4 Suppl. 1: S51-S65
10. Mittman N, Herrmann N, Einarson TR, et al. The efficacy, safety and tolerabilily of antidepressants in late life depression: a meta-analysis. J Affect Disord 1997; 46: 191-217
11. Mahapatra SN, Hackett D. A randomized, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patien'ts with major depression. Int J Clin Pract 1997; 51: 209-13
12. Preskorn S, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992; 53 Suppl. 9: 1-14
13. Danish University Antidepressant Group (DUAG). Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychophamacology 1986; 90: 131-8
14. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect, than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289-99
15. Danish University Antidepressant Group (DUAG). Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993; 28: 105-16
16. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996; 39: 1-6
17. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 1735-9
18. Georgotas A, McCue RE, Cooper TB, et al. How effective and safe is continuation therapy in elderly depressed patients? Arch Gen Psychiatry 1988; 45: 929-32
19. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriplyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989; 46: 783-6
20. Reynolds CF, Frank E, Perel JM, et al. Maintenance therapies for late-life recurrent major depression: research and review circa 1995. Int Psychogeriatr 1995; 7 Suppl.: 27-39
21. Old Age Depression Interest Group. How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiatry 1993; 162: 175-82
22. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21: 1155-66
23. Miller MD, Pollock BG, Rifai AH, et al. Longitudinal analysis of nortriptyline side effects in elderly depressed patients. J Geriatr Psychiatry Neurol 1991; 4: 226-30
24. Reynolds CF, Frank E, Perel JM, et al. Nortriptyline side effects during double-blind, randomised, placebo-controlled maintenance therapy in older depressed patients. Am J Geriatr Psychiatry 1995; 3: 170-5
25. Rosen J, Sweet R, Pollock BG, et al. Nortriptyline in the hospitalized elderly: tolerance and side effect reduction. Psychopharmacol Bull 1993; 29 (2): 327-31
26. Katz IR, Simpson GM, Curlick SM, et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990; 51 Suppl. 7: 41-7
27. Lipsey JR, Robinson RG, Pearlson GD, et al. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984; 1: 297-300
28. Koenig HG, Breitner JCS. Use of antidepressants in medically ill older patients. Psychosomatics 1990; 31: 22-32
29. Young RC, Mattis S, Alexopoulos GS, et al. Verbal memory and plasma drug concentrations in elderly depressives treated with nortriptyline. Psychopharmacol Bull 1991; 27 (3): 291-4
30. Meyers BS, Mattis S, Gabriele M, et al. Effects of nortriptyline on memory self-assessment and performance in recovered elderly depressives. Psychopharmacol Bull 1991; 27 (3): 295-9
31. Hoff AL, Shukla S, Helms P, et al. The effects of nortriptyline on cognition in elderly depressed patients. J Clin Psychopharmacol 1990; 10 (3): 231-2
32. Halper JP, Mann JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry 1988; 153 Suppl. 3: 87-98
33. Roose SP, Glassman AH, Giardina EGV, et al. Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986; 256: 3253-7
34. Roose SP, Dalack GW. Treating the depressed patient with cardiovascular problems. J Clin Psychiatry 1992; 53 Suppl 9.: 25-31
35. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the cardiac arrhythmia suppression trial (CAST) studies. J Clin Psychiatry 1994; 55 (9 Suppl. A): 83-7
36. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 94 (Suppl. 5A): 2-12S
37. Rockwell E, Lam RW, Zisook S. Antidepressant drug studies in the elderly. Psychiatr Clin North Am 1988; 11: 215-33
38. Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 1990; 18: 346-64
39. von Moltke LL, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of antidepressants in the elderly. Clin Pharmacokinet 1993; 24: 141-60
40. Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125-8
41. Pollock BG, Perel JM, Paradis CF, et al. Metabolic and physiologic consequences of nortriptyline treatment in the elderly. Psychopharmacol Bull 1994; 30 (2): 145-50
42. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP 2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992: 34: 262-5
43. Wakeling A. Efficacy and side effects of mianserin, a tetracyclic antidepressant. Postgrad Med J 1983; 59: 229-31
44. Kerr JS, Sherwood N, Hindmarch I. The comparative psychopharmacology of 5HT reuptake inhibitors. Hum Psychopharmacol 1991; 6: 313-7
45. Macquire KP, Norman TR, Burrows GD, et al. A pharmacokinetic study of mianserin. Eur J Clin Pharmacol 1982; 21: 517-22
46. Leinonen E, Koponen H, Lepola U. Serum mianserin and ageing. Prog Neuropsychopharmacol. Biol Psychiatry 1994; 18: 833-45
47. Shami M, Elliot HL, Kelman AT, et al. The pharmacokinetics of mianserin. Br J Clin Pharmacol 1983; 15: 313S-22S
48. Begg EG, Sharman JR, Kidd JE, et al. Variability in the elimination of mianserin in elderly patients. Br J Clin Pharmacol 1989; 27: 445-51
49. Sasa H. Steady state plasma kinetics of mianserin and its major metabolite desmethylmianserin. Jpn J Neuropsychopharmacology 1992; 14: 441-8
50. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994; 7: 307-30
51. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 1987; 93: 193-200
52. Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomised comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994; 9: 25-9
53. Grimsley SR, Jann MW. Paroxetine, sertraline and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11: 930-57
54. Sheehan D, Dunbar GC, Fuell DL. The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol Bull 1992; 28: 139-43
55. Tollefson GD, Greist JH, Jefferson JW, et al. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 1994; 14: 385-91
56. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990; 51 (12 Suppl. B): 9-12
57. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995; 56: 30-4
58. Laghrissi-Thode F, Pollock BG, Miller M, et al. Comparative effects of sertraline and nortriptyline on body sway in older depressed patients. Am J Geriatr Psychiatry 1995; 3: 217-28
59. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Can Med Assoc J 1996; 155: 519-27
60. Flint AJ, Crosby J, Genik JL. Recurrent hyponatremia associated with fluoxetine and paroxetine [letter]. Am J Psychiatry 1996; 153: 134
61. Mattila MJ, Saarialho-Kere U, Mattila M. Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age. J Clin Psychiatry 1988; 49 (8 Suppl.): 52-8
62. Hindmarch I, Shillingford J, Shillingford C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990; 51 (12 Suppl. B): 34-6
63. Hindmarsh I, Kerr JS. Effects of paroxetine on cognitive function in depressed patients, volunteers and elderly volunteers. Med Sci Res 1994; 22: 669-70
64. McEntee W, Oxman T, Ko G, et al. The effects of sertraline on cognition in depressed geriatric patients [abstract]. Psychopharmacol Bull 1996; 32 (3): 486
65. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 1997; 102: 54-9
66. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287-91
67. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311-20
68. Shader RI, von Moltke LL, Schmider J, et al. The clinician and drug interactions: an update. J Clin Psychopharmacol 1996; 16: 197-201
69. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors: part II. J Clin Psychopharmacol 1996; 16: 345-55
70. Newhouse PA. Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry 1996; 57 Suppl. 5: 12-22
71. Rifkin A. SSRI optimal dose remains at issue. J Clin Psychiatry 1997; 58: 87-8
72. De Vane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992; 53 Suppl. 2: 13-20
73. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12: 185-219
74. Mallinger AG, Smith F. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 1991; 27: 493-502
75. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996; 57 (3): 99-104
76. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord 1996; 36: 95-105
77. Georgotas A, Friedman L, McCarthy M, et al. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry 1983; 18 (2): 195-205
78. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607-15
79. Nair NPV, Ahmed SK, Ng Ying Kin NMK, et al. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr Scand 1995; 91 Suppl. 386: 28-35
80. Moll E, Hetzel W. Moclobemide safety in depressed patients. Acta Psychiatr Scand 1990; 82 Suppl. 360: 69-70
81. Wesnes KA, Simpson PM, Christmas L, et al. The effects of moclobemide on cognition. J Neural Transm 1989; 28 Suppl.: 91-102
82. Anand R, Wesnes KA. Cognition-enhancing effects of moclobemide, a reversible MAO-inhibitor, in humans. Adv Neurol 1990; 51: 261-8
83. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670-7
84. Stoeckel K, Pfefen JP, Mayersohn M, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand 1990; 82 Suppl. 360: 94-7
85. Nair NPV, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients, a randomized, multicenter trial against placebo. J Affect Disord 1995; 33: 1-9
86. Georgotas A, Thomas L, Forsell TL, et al. Trazodone hydrochloride: a wide spectrum antidepressant with a unique pharmacological profile: a review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology. Pharmacotherapy 1982; 2: 255-64
87. Murphy DL, Mueller EA, Hill JL, et al. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 1989; 98: 275-82
88. Barbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Pharmacol 1996; 42: 573-81
89. Nutt D. Early action of nefazodone in anxiety associated with depression. J Psychopharmacol 1996; 10 Suppl. 1: 18-21
90. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenler double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 Suppl. 2: 46-52
91. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 Suppl. 2: 31-8
92. van Laar MW, van Willigenburg APP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adults and elderly subjects. J Clin Psychopharmacol 1995; 15: 30-40
93. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996; 16: 19-25
94. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994; 55 (9 Suppl. A): 62-8
95. Rudorfer MV, Potter WA. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. Drugs 1989; 37: 713-38
96. Rudorfer MV, Potter WZ. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 1997; 7 (4): 273-312
97. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple- dose bupropion in elderly patients with depression. J Clin Pharmacol 1995; 35: 876-84